SubsidieMeestersHB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss
HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.
Projectdetails
Introduction
HB-086 and HB-097 comprise our portfolio of therapeutic proteins. They are a family of growth factors with actions on sensory nerve cells and represent novel treatment approaches and a paradigm shift for medical treatment and prevention of severe, chronic conditions such as pain and hearing loss.
Mechanism of Action
The drug candidates target sensory nerve cells and their support cells in dorsal root ganglia and the inner ear. Evidence indicates a mode of action including:
- Normalisation of impaired neuronal-glial crosstalk
- Protection and regeneration of sensory nerve fibres
These mechanisms underpin increased peripheral afferent drive associated with chronic pain and apoptotic hearing loss.
Preclinical Data
Preclinical data confirm that:
- HB-086 completely abolishes pain sensation across different models.
- HB-097 preserves the sense of hearing in relevant models.
Dosing and Disease Progression
Importantly, documented prolonged effects warrant biweekly or monthly dosing and prevention of further disease progression.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.325.312 |
| Totale projectbegroting | € 3.321.875 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 31-5-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- HOBA THERAPEUTICS APSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Homeoproteins as novel therapies for neurodegenerative diseasesBrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic painSea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment. | EIC Accelerator | € 2.499.035 | 2024 | Details |
A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.Salvia BioElectronics is developing PRIMUS, a dual-site peripheral nerve modulator for drug-refractory chronic headaches, aiming for market launch by 2026 after successful clinical trials. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
Homeoproteins as novel therapies for neurodegenerative diseases
BrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function.
Clinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain
Sea4Us aims to clinically validate its novel analgesic Sea4Pain for chronic pain treatment, facilitating rapid market entry and sustainable growth through licensing and reinvestment.
A new life for people with severe disabling cluster headache: Neuromodulation therapy using safe, minimally-invasive simultaneous stimulation at the front and back of the head.
Salvia BioElectronics is developing PRIMUS, a dual-site peripheral nerve modulator for drug-refractory chronic headaches, aiming for market launch by 2026 after successful clinical trials.
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
Pre-clinical development of a lentiviral gene therapy to treat hearing and balance loss in Usher 1B patientsThe MY(O)SENSES project aims to develop and commercialize a novel lentiviral gene therapy for Usher syndrome, targeting hearing loss and vertigo to improve patient outcomes. | ERC Proof of... | € 150.000 | 2022 | Details |
Molecules for Nociceptor Force TransductionThis project aims to identify and target specific molecules involved in nociceptor force transduction to develop new pain therapies. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Precision Hearing Diagnostics and Augmented-hearing TechnologiesThe project aims to develop a portable diagnostic device for cochlear synaptopathy and augmented-hearing technologies, transitioning innovative research into practical clinical applications. | EIC Transition | € 2.499.416 | 2022 | Details |
Targeting peripheral nerves: a method for therapeutic modulation of inflammatory disease with non-invasive temporal interferenceThe project aims to develop a non-invasive, patch-based nerve stimulator using Temporal Interference to precisely target inflammation-regulating nerves, enhancing treatment for inflammatory diseases. | ERC Proof of... | € 150.000 | 2023 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Pre-clinical development of a lentiviral gene therapy to treat hearing and balance loss in Usher 1B patients
The MY(O)SENSES project aims to develop and commercialize a novel lentiviral gene therapy for Usher syndrome, targeting hearing loss and vertigo to improve patient outcomes.
Molecules for Nociceptor Force Transduction
This project aims to identify and target specific molecules involved in nociceptor force transduction to develop new pain therapies.
Precision Hearing Diagnostics and Augmented-hearing Technologies
The project aims to develop a portable diagnostic device for cochlear synaptopathy and augmented-hearing technologies, transitioning innovative research into practical clinical applications.
Targeting peripheral nerves: a method for therapeutic modulation of inflammatory disease with non-invasive temporal interference
The project aims to develop a non-invasive, patch-based nerve stimulator using Temporal Interference to precisely target inflammation-regulating nerves, enhancing treatment for inflammatory diseases.